ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

ClinicalTrials.gov ID: NCT04211363

Public ClinicalTrials.gov record NCT04211363. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 2:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis

Study identification

NCT ID
NCT04211363
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Enrollment
439 participants

Conditions and interventions

Interventions

  • Roflumilast 0.3% cream Drug
  • Vehicle Cream Drug

Drug

Eligibility (public fields only)

Age range
2 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 19, 2019
Primary completion
Nov 15, 2020
Completion
Nov 15, 2020
Last update posted
Dec 6, 2022

2019 – 2020

United States locations

U.S. sites
31
U.S. states
15
U.S. cities
29
Facility City State ZIP Site status
Arcutis Biotherapeutics Clinical Site 127 Encinitas California 92024
Arcutis Biotherapeutics Clinical Site 112 Fremont California 94538
Arcutis Biotherapeutics Clinical Site 120 Irvine California 92697
Arcutis Biotherapeutics Clinical Site 123 San Diego California 92123
Arcutis Biotherapeutics Clinical Site 136 San Francisco California 94132
Arcutis Biotherapeutics Clinical Site 118 Delray Beach Florida 33484
Arcutis Biotherapeutics Clinical Site 131 Miami Florida 33174
Arcutis Biotherapeutics Clinical Site 137 Ocala Florida 34470
Arcutis Biotherapeutics Clinical Site 105 Sanford Florida 32771
Arcutis Biotherapeutics Clinical Site 114 Plainfield Illinois 46168
Arcutis Biotherapeutics Clinical Site 102 Rolling Meadows Illinois 60008
Arcutis Biotherapeutics Clinical Site 111 Baton Rouge Louisiana 70809
Arcutis Biotherapeutics Clinical Site 125 Rockville Maryland 20850
Arcutis Biotherapeutics Clinical Site 138 Rockville Maryland 20850
Arcutis Biotherapeutics Clinical Site 101 Brighton Massachusetts 02135
Arcutis Biotherapeutics Clinical Site 116 Clinton Township Michigan 48038
Arcutis Biotherapeutics Clinical Site 139 Reno Nevada 89509
Arcutis Biotherapeutics Clinical Site 129 East Windsor New Jersey 08520
Arcutis Biotherapeutics Clinical Site 121 New York New York 10029
Arcutis Biotherapeutics Clinical Site 130 Rochester New York 14623
Arcutis Biotherapeutics Clinical Site 108 Stony Brook New York 11790
Arcutis Biotherapeutics Clinical Site 115 High Point North Carolina 27262
Arcutis Biotherapeutics Clinical Site 124 Fairborn Ohio 45324
Arcutis Biotherapeutics Clinical Site 134 Oklahoma City Oklahoma 73118
Arcutis Biotherapeutics Clinical Site 128 Duncansville Pennsylvania 16635
Arcutis Biotherapeutics Clinical Site 113 Exton Pennsylvania 19003
Arcutis Biotherapeutics Clinical Site 135 Pittsburgh Pennsylvania 15213
Arcutis Biotherapeutics Clinical Site 104 College Station Texas 77845
Arcutis Biotherapeutics Clinical Site 119 Dallas Texas 75246
Arcutis Biotherapeutics Clinical Site 110 San Antonio Texas 78218
Arcutis Biotherapeutics Clinical Site 117 San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04211363, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 6, 2022 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04211363 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →